Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Cancer Res. 2019 Mar 15;79(9):2195–2207. doi: 10.1158/0008-5472.CAN-18-2133

Figure 7: Combined menin inhibition and gefitinib reduces colon cancer xenograft growth and suppresses SKP2.

Figure 7:

Nude mice were transplanted with HT-29 cells, and once tumor size reached approximately 100mm3, treatment was started with either gefitinib (100 mg/kg daily by oral gavage), MI-463 (35 mg/kg daily by IP/SQ injection), the combination of gefitinib plus MI-463, or vehicle control. A) Tumor size was measured with a Vernier caliber every 3 days. Error bars indicate +/− SEM. B) Mice were weighed every 3 days. Error bars indicate +/− SD. C-D) SKP2 immunofluorescence was performed in the xenografts with quantitation of SKP2 immunofluorescence (C) and representative images from each of the 4 treatment groups (D). E) A representative model of menin and iEGFR involvement in SKP2 regulation. * p < 0.05.